Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress
20 oct. 2021 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from...
Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
07 oct. 2021 08h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its...
Editas Medicine to Present at Chardan’s 5th Annual Genetic Medicines Conference
30 sept. 2021 08h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present at Chardan’s 5th Annual Genetic Medicines Conference on...
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
29 sept. 2021 09h00 HE
|
Editas Medicine, Inc.
No serious adverse events or dose-limiting toxicities observed to date Efficacy signals in the mid-dose cohort provide initial support for clinical benefits Treatment in the adult high-dose cohort...
Editas Medicine Names Emma Reeve to Board of Directors
08 sept. 2021 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Emma Reeve to its Board of...
Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September
07 sept. 2021 16h00 HE
|
Editas Medicine, Inc.
Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity Abstract selected for oral presentation on September 29 Company to host...
Editas Medicine to Participate in Upcoming Investor Conferences
02 sept. 2021 08h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following...
Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting
20 août 2021 16h20 HE
|
Editas Medicine, Inc.
SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells Data support SLEEK as an optimized approach to develop next...
Editas Medicine Announces Second Quarter 2021 Results and Business Updates
04 août 2021 07h00 HE
|
Editas Medicine, Inc.
Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10 EDIT-101 initial clinical data planned for September 2021 EDIT-301 RUBY trial for sickle cell...
Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines
29 juil. 2021 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass. and CORALVILLE, Iowa, July 29, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Integrated DNA Technologies, Inc. (IDT), a...